Ascendis Pharma maintained as Outperform; Oppenheimer lifts PT to $312
Oppenheimer maintained its Outperform rating on Ascendis Pharma and raised its price target to $312.00 per share from $304.00, according to TradingView News/Benzinga ratings coverage.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.